{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:13:29Z","timestamp":1782886409345,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373717"],"award-info":[{"award-number":["82373717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82125037"],"award-info":[{"award-number":["82125037"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308200"],"award-info":[{"award-number":["2023YFC2308200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tstp20231239"],"award-info":[{"award-number":["tstp20231239"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118667","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:42:21Z","timestamp":1771400541000},"page":"118667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia"],"prefix":"10.1016","volume":"308","author":[{"given":"Qingyun","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118667_bib1","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118667_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118667_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118667_bib4","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.ddstr.2011.12.002","article-title":"Bromodomains: a new target class for small molecule drug discovery","volume":"9","author":"Chung","year":"2012","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.ejmech.2026.118667_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118667_bib6","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acs.jmedchem.1c01835","article-title":"Targeting bromodomain-selective inhibitors of BET proteins in drug discovery and development","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib7","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1021\/acsmedchemlett.9b00474","article-title":"Pharmacokinetics-driven optimization of 7-Methylimidazo[1,5-a]pyrazin-8(7H)-one as novel BRD4 inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118667_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115857","article-title":"Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors","volume":"29","author":"Yang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib9","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1021\/acsmedchemlett.0c00294","article-title":"Identification of 3,5-Dimethylisoxazole derivatives as BRD4 inhibitors for the treatment of colorectal cancer","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118667_bib10","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118667_bib11","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.118667_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118667_bib13","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2019","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.ejmech.2026.118667_bib14","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1073\/pnas.1919507117","article-title":"MYC protein stability is negatively regulated by BRD4","volume":"117","author":"Devaiah","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118667_bib15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118667_bib16","first-page":"1","article-title":"PROTAC targeted protein degraders: the past is prologue","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118667_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118667_bib18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118667_bib19","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib20","first-page":"1","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E","author":"Posternak","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118667_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.118667_bib22","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118667_bib23","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines","volume":"199","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib25","doi-asserted-by":"crossref","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118667_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib27","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","article-title":"Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression","volume":"61","author":"Qin","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ddtec.2019.04.001","article-title":"Small-molecule PROTAC degraders of the bromodomain and extra terminal (BET) proteins \u2014 a review","volume":"31","author":"Yang","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.118667_bib29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118667_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118667_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118667_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115181","article-title":"Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies","volume":"28","author":"Jiang","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib33","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-based design of a macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118667_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115228","article-title":"Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide\/pomalidomide","volume":"28","author":"Zhang","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103817","article-title":"Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative","volume":"99","author":"Zhang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","article-title":"Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity","volume":"17","author":"Imaide","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118667_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting \u201cUndruggable\u201d Myc-pathway genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2026.118667_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114259","article-title":"Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold","volume":"236","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113922","article-title":"Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET\/PLK1 inhibitor","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib40","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib41","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1039\/D2CS00148A","article-title":"E3 ligase ligand chemistries: from building blocks to protein degraders","volume":"51","author":"Sosi\u010d","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118667_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4 CRBN ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118667_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118667_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118667_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4 CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118667_bib46","article-title":"AML-147 C-MYC targeting by degradation: novel dual c-Myc\/GSPT1 degrader GT19715 exerts profound cell kill in vitro and in vivo in acute myeloid leukemia and lymphomas","volume":"22","author":"Nishida","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2026.118667_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118667_bib48","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jmedchem.1c01832","article-title":"Development of PDE6D and CK1\u03b1 degraders through chemical derivatization of FPFT-2216","volume":"65","author":"Teng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118667_bib49","doi-asserted-by":"crossref","first-page":"eado6492","DOI":"10.1126\/sciadv.ado6492","article-title":"Mechanism of degrader-targeted protein ubiquitinability","volume":"10","author":"Crowe","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118667_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2050.2050","article-title":"BRD4 degradation by protacs represents a more effective therapeutic strategy than BRD4 inhibitors in DLBCL","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:10:43Z","timestamp":1779743443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S0223523426001121"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118667","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118667"}}